Theodosios D Filippatos

List of Publications by Citations

Source: https://exaly.com/author-pdf/3215536/theodosios-d-filippatos-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119 papers	3,763 citations	36 h-index	53 g-index
138 ext. papers	4,313 ext. citations	3.6 avg, IF	5.66 L-index

#	Paper	IF	Citations
119	Orlistat-associated adverse effects and drug interactions: a critical review. *Drug Safety*, **2008**, 31, 53-65	5.1	217
118	Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. *Clinical Chemistry*, **2005**, 51, 2264-73	5.5	146
117	Adverse Effects of GLP-1 Receptor Agonists. *Review of Diabetic Studies*, **2014**, 11, 202-30	3.6	119
116	Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. *Journal of Endocrinological Investigation*, **2007**, 30, 323-6	5.2	97
115	Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. *Current Medical Research and Opinion*, **2005**, 21, 1997-2006	2.5	90
114	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. *Current Medical Research and Opinion*, **2007**, 23, 1169-76	2.5	88
113	Statin-associated adverse effects beyond muscle and liver toxicity. *Atherosclerosis*, **2007**, 195, 7-16	3.1	86
112	A review of the metabolic effects of sibutramine. *Current Medical Research and Opinion*, **2005**, 21, 457-68	2.5	85
111	A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. *Metabolism: Clinical and Experimental*, **2012**, 61, 906-21	12.7	83
110	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. *Atherosclerosis*, **2007**, 193, 428-37	3.1	82
109	Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. *Journal of Rheumatology*, **2006**, 33, 921-3	4.1	68
108	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. *Lipids*, **2006**, 41, 647-54	1.6	66
107	Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. *Metabolism: Clinical and Experimental*, **2006**, 55, 885-91	12.7	64
106	Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. *Lipids*, **2009**, 44, 9-16	1.6	63
105	Increased plasma visfatin levels in subjects with the metabolic syndrome. *European Journal of Clinical Investigation*, **2008**, 38, 71-2	4.6	60
104	The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. *Current Medical Research and Opinion*, **2008**, 24, 1919-29	2.5	59
103	The effects of orlistat on metabolic parameters and other cardiovascular risk factors. *Diabetes and Metabolism*, **2005**, 31, 15-22	5.4	59

102	Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). *Current Medical Research and Opinion*, **2006**, 22, 1123-31	2.5	55
101	The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. *Diabetes, Obesity and Metabolism*, **2008**, 10, 476-83	6.7	52
100	Visfatin/PBEF and atherosclerosis-related diseases. *Current Vascular Pharmacology*, **2010**, 8, 12-28	3.3	51
99	Hyponatremia in the elderly: challenges and solutions. *Clinical Interventions in Aging*, **2017**, 12, 1957-1965	4	49
98	Obesity and arterial compliance alterations. *Current Vascular Pharmacology*, **2010**, 8, 155-68	3.3	49
97	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. *Journal of Hypertension*, **2018**, 36, 1427-1440	1.9	48
96	Electrolyte disorders associated with the use of anticancer drugs. *European Journal of Pharmacology*, **2016**, 777, 78-87	5.3	48
95	Effects of glucagon-like peptide-1 receptor agonists on renal function. *World Journal of Diabetes*, **2013**, 4, 190-201	4.7	47
94	Treatment of hyperlipidaemia with fenofibrate and related fibrates. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1599-614	5.9	45
93	A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. *Clinical Therapeutics*, **2007**, 29, 1403-14	3.5	45
92	SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. *Postgraduate Medicine*, **2019**, 131, 82-88	3.7	44
91	Hyponatremia in patients with heart failure. *World Journal of Cardiology*, **2013**, 5, 317-28	2.1	43
90	Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2010**, 15, 120-34	2.6	43
89	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. *Expert Opinion on Drug Metabolism and Toxicology*, **2014**, 10, 787-812	5.5	42
88	Lipid-lowering drugs acting at the level of the gastrointestinal tract. *Current Pharmaceutical Design*, **2009**, 15, 490-516	3.3	41
87	Effects of hormonal treatment on lipids in patients with cancer. *Cancer Treatment Reviews*, **2009**, 35, 175-84	14.4	41
86	SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2018**, 12, 59-63	8.9	37
85	Alterations in electrolyte equilibrium in patients with acute leukemia. *European Journal of Haematology*, **2005**, 75, 449-60	3.8	37

84	SGLT2 inhibitors: are they safe?. *Postgraduate Medicine*, **2018**, 130, 72-82	3.7	36
83	Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. *Nutrition, Metabolism and Cardiovascular Diseases*, **2008**, 18, 477-82	4.5	35
82	Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. *Atherosclerosis*, **2006**, 187, 170-6	3.1	34
81	The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 3151-8	4	31
80	Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. *Fundamental and Clinical Pharmacology*, **2009**, 23, 595-600	3.1	29
79	Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2009**, 14, 5-13	2.6	27
78	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. *Journal of Hypertension*, **2018**, 36, 1441-1455	1.9	26
77	Ten common pitfalls in the evaluation of patients with hyponatremia. *European Journal of Internal Medicine*, **2016**, 29, 22-5	3.9	26
76	SGLT2 inhibitors and the kidney: Effects and mechanisms. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2018**, 12, 1117-1123	8.9	26
75	MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. *European Journal of Endocrinology*, **2017**, 176, R15-R20	6.5	26
74	Mediterranean Diet and 10-year (2002-2012) Incidence of Diabetes and Cardiovascular Disease in Participants with Prediabetes: The ATTICA study. *Review of Diabetic Studies*, **2016**, 13, 226-235	3.6	26
73	Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?. *Review of Diabetic Studies*, **2013**, 10, 171-90	3.6	25
72	Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. *European Journal of Pharmacology*, **2008**, 578, 249-52	5.3	25
71	Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2008**, 18, 207-10	4.5	25
70	Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. *Journal of Geriatric Cardiology*, **2016**, 13, 175-82	1.7	25
69	Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A□n subjects with prediabetes. *Lipids*, **2013**, 48, 547-55	1.6	24
68	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 2605-11	4	24
67	LDL cholesterol estimation in patients with the metabolic syndrome. *Lipids in Health and Disease*, **2006**, 5, 8	4.4	24

66	Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy. *Postgraduate Medicine*, **2015**, 127, 405-12	3.7	23
65	Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1581-3	4	23
64	Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. *Scandinavian Journal of Rheumatology*, **2013**, 42, 169-75	1.9	22
63	The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. *Lipids*, **2010**, 45, 445-50	1.6	22
62	Cholesteryl ester transfer protein inhibitors: challenges and perspectives. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 953-62	2.5	22
61	Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes. *Disease Markers*, **2019**, 2019, 6578327	3.2	21
60	Pharmacological management of diabetic dyslipidemia. *Expert Review of Clinical Pharmacology*, **2017**, 10, 187-200	3.8	21
59	Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. *Lipids*, **2011**, 46, 953-60	1.6	21
58	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1945-58	4	21
57	Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2018**, 23, 3-12	2.6	20
56	Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise. *Hepatology International*, **2016**, 10, 762-72	8.8	20
55	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. *Lipids*, **2011**, 46, 521-8	1.6	20
54	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. *Archives of Medical Science*, **2013**, 9, 788-95	2.9	19
53	Safety considerations with fenofibrate/simvastatin combination. *Expert Opinion on Drug Safety*, **2015**, 14, 1481-93	4.1	18
52	Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition. *Current Vascular Pharmacology*, **2017**, 15, 96-102	3.3	18
51	Dapagliflozin in patients with type 2 diabetes mellitus. *Therapeutic Advances in Endocrinology and Metabolism*, **2015**, 6, 29-41	4.5	18
50	Combination of fenofibrate with non-statin drug regimens. *Current Pharmaceutical Design*, **2010**, 16, 3401-16	3.3	18
49	Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. *Journal of Clinical Lipidology*, **2008**, 2, 279-84	4.9	18

48	Combination drug treatment in patients with non-alcoholic fatty liver disease. *World Journal of Hepatology*, **2010**, 2, 139-42	3.4	18
47	SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 1113-1121	5.5	17
46	The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. *Obesity Reviews*, **2020**, 21, e13077	10.6	16
45	A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. *Cardiovascular Drugs and Therapy*, **2012**, 26, 245-55	3.9	16
44	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. *Expert Review of Cardiovascular Therapy*, **2011**, 9, 355-66	2.5	16
43	Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 1829-37	4	16
42	Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?. *Angiology*, **2005**, 56, 585-92	2.1	16
41	Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 330-6	4.5	15
40	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 399-408	5.5	15
39	Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. *Atherosclerosis*, **2010**, 208, 506-11	3.1	15
38	Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. *European Journal of Neurology*, **2007**, 14, 762-9	6	15
37	Role of ezetimibe in non-alcoholic fatty liver disease. *World Journal of Hepatology*, **2011**, 3, 265-7	3.4	15
36	High density lipoprotein and cardiovascular diseases. *World Journal of Cardiology*, **2013**, 5, 210-4	2.1	15
35	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. *Current Opinion in Lipidology*, **2018**, 29, 333-339	4.4	15
34	Pathophysiology of Diabetic Dyslipidaemia. *Current Vascular Pharmacology*, **2017**, 15, 566-575	3.3	14
33	Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 1629-39	4	14
32	Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities. *International Urology and Nephrology*, **2018**, 50, 91-96	2.3	13
31	Evaluation and treatment of hypernatremia: a practical guide for physicians. *Postgraduate Medicine*, **2016**, 128, 299-306	3.7	13

30	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. *Expert Opinion on Drug Safety*, **2016**, 15, 559-69	4.1	13
29	Use of intravenous fluids/solutions: a narrative review. *Current Medical Research and Opinion*, **2017**, 33, 459-471	2.5	13
28	Phosphate imbalance in patients with heart failure. *Heart Failure Reviews*, **2017**, 22, 349-356	5	12
27	Treatment of hyponatremia: the role of lixivaptan. *Expert Review of Clinical Pharmacology*, **2014**, 7, 431-438	3.8	12
26	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. *Expert Opinion on Drug Safety*, **2017**, 16, 1121-1132	4.1	12
25	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. *Diseases (Basel, Switzerland)*, **2017**, 5,	4.4	12
24	Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 2741-50	4	12
23	Serum osmolal gap in clinical practice: usefulness and limitations. *Postgraduate Medicine*, **2017**, 129, 456-459	3.7	11
22	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2019**, 24, 315-322	2.6	11
21	Non-hemorrhage-related adverse effects of rivaroxaban. *Archives of Medical Sciences Atherosclerotic Diseases*, **2017**, 2, e108-e112	0.9	11
20	Recommendations for severe hypertriglyceridemia treatment, are there new strategies?. *Current Vascular Pharmacology*, **2014**, 12, 598-616	3.3	11
19	Ten pitfalls in the proper management of patients with hyponatremia. *Postgraduate Medicine*, **2016** , 128, 516-22	3.7	11
18	Combination drug treatment in obese diabetic patients. *World Journal of Diabetes*, **2010**, 1, 8-11	4.7	10
17	Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. *Archives of Medical Sciences Atherosclerotic Diseases*, **2017**, 2, e46-e51	0.9	9
16	Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. *Clinical Lipidology*, **2009**, 4, 331-341		9
15	Statins and heart failure. *Angiology*, **2008**, 59, 58S-61S	2.1	9
14	Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. *Diabetes/Metabolism Research and Reviews*, **2008**, 24, 223-30	7.5	9
13	Apolipoprotein CIII and diabetes. Is there a link?. *Diabetes/Metabolism Research and Reviews*, **2019**, 35, e3118	7.5	8

12	Effects of ezetimibe/simvastatin combination on metabolic parameters. *International Journal of Cardiology*, **2016**, 202, 273-4	3.2	7
11	Pitavastatin and carbohydrate metabolism: what is the evidence?. *Expert Review of Clinical Pharmacology*, **2016**, 9, 955-60	3.8	7
10	Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. *Clinical Pharmacology: Advances and Applications*, **2019**, 11, 133-143	1.5	6
9	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. *Current Vascular Pharmacology*, **2019**, 17, 332-340	3.3	5
8	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. *Current Atherosclerosis Reports*, **2021**, 23, 20	6	5
7	Current lipid-modifying agents. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1117-8	4	4
6	Pharmacological management of hyponatremia. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1337-1344	4	4
5	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. *Journal of Stroke and Cerebrovascular Diseases*, **2021**, 30, 105708	2.8	4
4	Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 117-125	5.5	4
3	Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis. *Digestive Diseases and Sciences*, **2021**, 1	4	4
2	Modeling anthropometric indices in relation to 10-year (2002-2012) incidence of cardiovascular disease, among apparently healthy individuals: The ATTICA study. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2017**, 11 Suppl 2, S789-S795	8.9	3
1	Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2018**, 23, 187-191	2.6	2